Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Bone Marrow Transplant Rejection - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 13 Sep 17

The "Bone Marrow Transplant Rejection - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 22, 12, 47, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 14 and 2 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Bone Marrow Transplant Rejection - Overview
  3. Bone Marrow Transplant Rejection - Therapeutics Development
  4. Bone Marrow Transplant Rejection - Therapeutics Assessment
  5. Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development
  6. Bone Marrow Transplant Rejection - Drug Profiles
  7. Bone Marrow Transplant Rejection - Dormant Projects
  8. Bone Marrow Transplant Rejection - Discontinued Products
  9. Bone Marrow Transplant Rejection - Product Development Milestones
  10. Appendix

Companies Mentioned

  • AbbVie Inc
  • AbGenomics International Inc
  • Aptevo Therapeutics Inc
  • arGEN-X BV
  • Athersys Inc
  • Bellicum Pharmaceuticals Inc
  • Bio-Cancer Treatment International Ltd
  • Biogen Inc
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • Cytodyn Inc
  • Escape Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Generon (Shanghai) Corp Ltd
  • Gilead Sciences Inc
  • Kadmon Corp LLC
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kymab Ltd
  • Kyorin Pharmaceutical Co Ltd
  • MacroGenics Inc
  • Mallinckrodt Plc
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • Pluristem Therapeutics Inc
  • Sanofi
  • Sarepta Therapeutics Inc
  • Seattle Genetics Inc
  • Seres Therapeutics Inc
  • Sigmoid Pharma Ltd
  • United BioPharma Inc
  • ZIOPHARM Oncology Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 13/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.